Comparative Analysis of the Efficacy of Abrocitinib and Dupilumab in the Treatment of Atopic Dermatitis.

Clin Cosmet Investig Dermatol · 2025 · PMC11986647 · PMID 40225313

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

24 , 25 The slightly higher incidence of adverse reactions in the Dupilumab group may be due to the larger sample size or individual patient variability, but this difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.